# Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease

> **NCT01868997** · PHASE2 · COMPLETED · sponsor: **Amgen** · enrollment: 88 (actual)

## Conditions studied

- Thyroid Associated Ophthalmopathies
- Thyroid-Associated Ophthalmopathy

## Interventions

- **DRUG:** teprotumumab
- **DRUG:** normal saline

## Key facts

- **NCT ID:** NCT01868997
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-03
- **Final completion:** 2017-02-22
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2024-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01868997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01868997, "Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01868997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*